Corporate Presentation Aug 2025 Safe Harbor This presentation contains "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Harrow, Inc. (the "Company ...

Financial Performance and Projections - 2025 revenue is expected to be more than $280 million[7] - Adjusted EBITDA for 2024 was $40327 thousand[10] - Consolidated revenues for 2024 were $199614 thousand[10] - ImprimisRx generated $83499 thousand in revenues in 2024[26] Product Launches and Performance - VEVYE Access for All launched in mid-March 2025, leading to a fourfold increase in weekly new prescriptions and prescribers in the first seven weeks[8] - IHEEZO customer unit demand in Q1 2025 reached 38940[14] - VEVYE quarterly prescriptions in Q1 2025 were 72017[17] Strategic Investments and Developments - Harrow holds a 46% ownership in Melt Pharmaceuticals[8] - Melt Pharmaceuticals' MELT-300 showed positive Phase 3 efficacy results, with potential FDA approval and launch in Q1 2027[8] - TRIESENCE has pass-through status granted by CMS effective April 1, 2025[23]

Financial Performance - Revenues for Q4 2024 reached $66.8 million, and for the full year 2024, revenues were $199.6 million[7] - GAAP net income for Q4 2024 was $6.8 million, while the GAAP net loss for the full year 2024 was $(17.5) million[7] - Core net income for Q4 2024 was $11.4 million, and the core net loss for the full year 2024 was $2.1 million[7] - Adjusted EBITDA was $22.5 million for Q4 2024 and $40.3 million for the full year 2024[7] - Gross margin was 79% for Q4 2024 and 75% for the full year 2024[7] - Core gross margin was 84% for Q4 2024 and 80% for the full year 2024[7] - Harrow projects consolidated revenues of $280 million for 2025[9] Product Performance - IHEEZO quarterly customer unit demand increased sequentially, reaching 49,130 units in Q4 2024[13] - VEVYE quarterly prescriptions also increased, reaching 63,925 in Q4 2024[16] ImprimisRx - ImprimisRx revenues were $83.499 million in 2024[24] Melt Pharmaceuticals - Harrow owns 46% equity ownership in Melt Pharmaceuticals[27] - Positive topline Phase 3 clinical data for MELT-300 was reported in Q4 2024[29]